ProfileGDS5678 / 1420592_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 93% 94% 93% 94% 95% 92% 93% 94% 94% 93% 94% 94% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.1263794
GSM967853U87-EV human glioblastoma xenograft - Control 27.9891593
GSM967854U87-EV human glioblastoma xenograft - Control 38.2808294
GSM967855U87-EV human glioblastoma xenograft - Control 48.084993
GSM967856U87-EV human glioblastoma xenograft - Control 58.1416994
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.0619895
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.522292
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.8623793
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.0259394
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.126394
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.924993
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.0768194
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.1575794
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.0660894